Immunocore (IMCR) Price Target Raised on Melanoma Trial Results

Jefferies has raised its price target for Immunocore (IMCR), reflecting positive developments from recent melanoma trial results. This adjustment comes as the firm acknowledges the promising potential of Immunocore's therapies in oncology. A specific target price has not been disclosed in the article, but such revisions typically influence investor sentiment and stock performance. An increase in price target could attract more investment, impacting market activity and confidence in IMCR.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.